|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-6-12
|
|
pubmed:abstractText |
Daunorubicin is an anthracycline anti-tumor agent; anthracycline chemotherapy in cancer can cause severe cardiomyopathy leading to a frequently fatal congestive heart failure; the first-line treatment is diuretics and digoxin. Recently, angiotensin-converting enzyme inhibitors have been shown to be effective in the treatment of such toxicity. The purpose of this study was to investigate the effects of angiotensin II type-1 receptor antagonist (candesartan) in a rat model of daunorubicin-induced cardiomyopathy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 2 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Atp2a2 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium-Transporting ATPases,
http://linkedlifedata.com/resource/pubmed/chemical/Daunorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fas Ligand Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Sarcoplasmic Reticulum...,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Tnfsf6 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factors,
http://linkedlifedata.com/resource/pubmed/chemical/candesartan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0167-5273
|
|
pubmed:author |
pubmed-author:AizawaYoshifusaY,
pubmed-author:KamalFadia AFA,
pubmed-author:KodamaMakotoM,
pubmed-author:KunisakiMegumiM,
pubmed-author:MeijerMM,
pubmed-author:MitoSayakaS,
pubmed-author:PrakashParasP,
pubmed-author:SogaMayakoM,
pubmed-author:SureshPalaniyandiP,
pubmed-author:TachikawaHitoshiH,
pubmed-author:VeeraveeduPunniyakotiP,
pubmed-author:WatanabeKenichiK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
28
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
378-85
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16324756-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:16324756-Angiotensin II Type 2 Receptor Blockers,
pubmed-meshheading:16324756-Animals,
pubmed-meshheading:16324756-Apoptosis,
pubmed-meshheading:16324756-Benzimidazoles,
pubmed-meshheading:16324756-Blood Pressure,
pubmed-meshheading:16324756-Body Weight,
pubmed-meshheading:16324756-Calcium-Transporting ATPases,
pubmed-meshheading:16324756-Cardiomyopathies,
pubmed-meshheading:16324756-Cytoprotection,
pubmed-meshheading:16324756-Daunorubicin,
pubmed-meshheading:16324756-Disease Models, Animal,
pubmed-meshheading:16324756-Electrocardiography,
pubmed-meshheading:16324756-Fas Ligand Protein,
pubmed-meshheading:16324756-Male,
pubmed-meshheading:16324756-Membrane Glycoproteins,
pubmed-meshheading:16324756-Organ Size,
pubmed-meshheading:16324756-RNA, Messenger,
pubmed-meshheading:16324756-Rats,
pubmed-meshheading:16324756-Rats, Sprague-Dawley,
pubmed-meshheading:16324756-Receptor, Angiotensin, Type 2,
pubmed-meshheading:16324756-Sarcoplasmic Reticulum Calcium-Transporting ATPases,
pubmed-meshheading:16324756-Survival Rate,
pubmed-meshheading:16324756-Tetrazoles,
pubmed-meshheading:16324756-Tumor Necrosis Factors
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
